Thompson Davis & Co’s iRadimed IRMD Stock Holding History

Thompson Davis & Co’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-100	Closed	-$2K	–	754
2018 Q2	$2K	Buy	+100	New	+$1.77K	﹤0.01%	613

Other funds holding IRMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Navellier & Associates Reno, Nevada $960M AUM 79.37% 1-Year Est. Return

CCM

Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Thompson Davis & Co's IRMD Position: Q3 2018 in Review

Thompson Davis & Co sold out of iRadimed (IRMD) in Q3 2018, closing a stake of 100 shares — an estimated $2K sold.

Thompson Davis & Co first reported a position in IRMD in Q2 2018 and held it in 1 quarter. The position peaked at $2K in Q2 2018. 68 funds tracked by Wall St. Rank hold IRMD as of Q3 2018.

Thompson Davis & Co reported no remaining iRadimed position as of Q3 2018 after selling out during the quarter.
Thompson Davis & Co sold 100 iRadimed shares in Q3 2018, an estimated $2K.
Thompson Davis & Co first reported a position in iRadimed in Q2 2018 and held it in 1 quarter.
Thompson Davis & Co's iRadimed position peaked at $2K in Q2 2018.
68 funds tracked by Wall St. Rank held iRadimed as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.